{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:26:47Z","timestamp":1792740407859,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individualization of the follicle-stimulating hormone (FSH) starting dose is considered standard clinical practice during controlled ovarian stimulation (COS) in patients undergoing assisted reproductive technology (ART) treatment. Furthermore, the gonadotropin dose is regularly adjusted during COS to avoid hyper- or hypo-ovarian response, but limited data are currently available to characterize such adjustments. This review describes the frequency and direction (increase\/decrease) of recombinant-human FSH (r-hFSH) dose adjustment reported in clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated the proportion of patients undergoing ART treatment who received \u2265\u00a01 r-hFSH dose adjustments. The inclusion criteria included studies (published Sept 2007 to Sept 2017) in women receiving ART treatment that allowed dose adjustment within the study protocol and that reported \u2265\u00a01 dose adjustments of r-hFSH; studies not allowing\/reporting dose adjustment were excluded. Data on study design, dose adjustment and patient characteristics were extracted. Point-incidence estimates were calculated per study and overall based on pooled number of cycles with dose adjustment across studies. The Clopper\u2013Pearson method was used to calculate 95% confidence intervals (CI) for incidence where adjustment occurred in &lt;\u200910% of patients; otherwise, a normal approximation method was used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Initially, 1409 publications were identified, of which 318 were excluded during initial screening and 1073 were excluded after full text review for not meeting the inclusion criteria. Eighteen studies (6630\u2009cycles) reported dose adjustment: 5\/18 studies (1359\u2009cycles) reported data for an unspecified dose adjustment (direction not defined), in 10\/18 studies (3952\u2009cycles) dose increases were reported, and in 11\/18 studies (5123\u2009cycles) dose decreases were reported. The studies were performed in women with poor, normal and high response, with one study reporting in oocyte donors and one in obese women. The median day that dose adjustment was permitted was Day 6 after the start of treatment. The point estimates for incidence (95% CI) for unspecified dose adjustment, dose increases, and dose decreases were 45.3% (42.7, 48.0), 19.2% (18.0, 20.5), and 9.5% (8.7, 10.3), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This systematic review highlights that, in studies in which dose adjustment was allowed and reported, the estimated incidence of r-hFSH dose adjustments during ovarian stimulation was up to 45%.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12958-021-00744-x","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T05:04:26Z","timestamp":1620709466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007\u20132017)"],"prefix":"10.1186","volume":"19","author":[{"given":"Human","family":"Fatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"La Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u2019Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"issue":"6","key":"744_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/humrep\/deu070","volume":"29","author":"M Ruiz-Alonso","year":"2014","unstructured":"Ruiz-Alonso M, Galindo N, Pellicer A, Simon C. What a difference two days make: \"personalized\" embryo transfer (pET) paradigm: a case report and pilot study. Hum Reprod. 2014;29(6):1244\u20137.","journal-title":"Hum Reprod"},{"key":"744_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fendo.2018.00033","volume":"9","author":"B Lawrenz","year":"2018","unstructured":"Lawrenz B, Samir S, Garrido N, Melado L, Engelmann N, Fatemi HM. Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturation-A Retrospective Proof-of-Concept Study. Front Endocrinol (Lausanne). 2018;9:33.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"744_CR3","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.fertnstert.2018.04.037","volume":"109","author":"BW Mol","year":"2018","unstructured":"Mol BW, Bossuyt PM, Sunkara SK, Garcia Velasco JA, Venetis C, Sakkas D, et al. Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients. Fertil Steril. 2018;109(6):968\u201379. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.04.037.","journal-title":"Fertil Steril"},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fendo.2019.00429","volume":"10","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Alam V, D'Hooghe T, Sunkara SK. The Development of Gonadotropins for Clinical Use in the Treatment of Infertility. Front Endocrinol (Lausanne). 2019;10:429.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"744_CR5","unstructured":"EMA. Puregon: Sumamry of product characteristics. 2021."},{"key":"744_CR6","unstructured":"EMA. Gonal-f: summary of product characteristics. 2020."},{"issue":"1","key":"744_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1477-7827-10-9","volume":"10","author":"C Alviggi","year":"2012","unstructured":"Alviggi C, Humaidan P, Ezcurra D. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol. 2012;10(1):9. https:\/\/doi.org\/10.1186\/1477-7827-10-9.","journal-title":"Reprod Biol Endocrinol"},{"key":"744_CR8","doi-asserted-by":"crossref","unstructured":"Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI). Cochrane Database Syst Rev.\u00a02018;2(2):Cd012693.","DOI":"10.1002\/14651858.CD012693.pub2"},{"issue":"2","key":"744_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BC, Garcia-Velasco JA, Klein BM, Arce JC. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility Sterility. 2017;107(2):387\u201396 e4.","journal-title":"Fertility Sterility"},{"issue":"4","key":"744_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.fertnstert.2012.11.051","volume":"99","author":"SM Nelson","year":"2013","unstructured":"Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99(4):963\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.11.051.","journal-title":"Fertil Steril"},{"issue":"3","key":"744_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4274\/jtgga.2017.0058","volume":"18","author":"G Sighinolfi","year":"2017","unstructured":"Sighinolfi G, Grisendi V, La Marca A. How to personalize ovarian stimulation in clinical practice. J Turk Ger Gynecol Assoc. 2017;18(3):148\u201353. https:\/\/doi.org\/10.4274\/jtgga.2017.0058.","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"744_CR12","doi-asserted-by":"crossref","unstructured":"Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker-The Follicle-To-Oocyte (FOI) Index. Front Endocrinol (Lausanne). 2018;9:589.","DOI":"10.3389\/fendo.2018.00589"},{"issue":"12","key":"744_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/09513590.2019.1650345","volume":"35","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Kirsten J, D'Hooghe T, Sunkara SK. Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility. Gynecol Endocrinol. 2019;35(12):1027\u201336. https:\/\/doi.org\/10.1080\/09513590.2019.1650345.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"744_CR14","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","volume":"2020","author":"E Bosch","year":"2020","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009.","journal-title":"Hum Reprod Open"},{"issue":"2","key":"744_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/humupd\/dmp036","volume":"16","author":"A La Marca","year":"2010","unstructured":"La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113\u201330. https:\/\/doi.org\/10.1093\/humupd\/dmp036.","journal-title":"Hum Reprod Update"},{"issue":"9","key":"744_CR16","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/humrep\/dem204","volume":"22","author":"SM Nelson","year":"2007","unstructured":"Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007;22(9):2414\u201321.","journal-title":"Hum Reprod"},{"issue":"3","key":"744_CR17","first-page":"265","volume":"18","author":"MR Sadeghi","year":"2017","unstructured":"Sadeghi MR. How can personalized medicine improve assisted reproduction technology outcomes? J Reprod Infertil. 2017;18(3):265\u20136.","journal-title":"J Reprod Infertil"},{"issue":"10","key":"744_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1471-0528.2012.03412.x","volume":"119","author":"A La Marca","year":"2012","unstructured":"La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. Bjog. 2012;119(10):1171\u20139. https:\/\/doi.org\/10.1111\/j.1471-0528.2012.03412.x.","journal-title":"Bjog."},{"issue":"2","key":"744_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-016-0126-z","volume":"16","author":"TH Rose","year":"2016","unstructured":"Rose TH, Roshammar D, Erichsen L, Grundemar L, Ottesen JT. Characterisation of population pharmacokinetics and endogenous follicle-stimulating hormone (FSH) levels after multiple dosing of a recombinant human FSH (FE 999049) in healthy women. Drugs R D. 2016;16(2):165\u201372. https:\/\/doi.org\/10.1007\/s40268-016-0126-z.","journal-title":"Drugs R D"},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.12688\/f1000research.10382.1","volume":"5","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. F1000Res. 2016;5:2911.","journal-title":"F1000Res"},{"issue":"12","key":"744_CR21","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/humrep\/dex321","volume":"32","author":"TC van Tilborg","year":"2017","unstructured":"van Tilborg TC, Oudshoorn SC, Eijkemans MJC, Mochtar MH, van Golde RJT, Hoek A, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF\/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017;32(12):2485\u201395.","journal-title":"Hum Reprod"},{"issue":"7","key":"744_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/1933719111432859","volume":"19","author":"P Kovacs","year":"2012","unstructured":"Kovacs P, Sajgo A, Kaali SG, Pal L. Detrimental effects of high-dose gonadotropin on outcome of IVF: making a case for gentle ovarian stimulation strategies. Reprod Sci. 2012;19(7):718\u201324. https:\/\/doi.org\/10.1177\/1933719111432859.","journal-title":"Reprod Sci"},{"issue":"5","key":"744_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1472-6483(10)60654-2","volume":"13","author":"JR Martin","year":"2006","unstructured":"Martin JR, Mahutte NG, Arici A, Sakkas D. Impact of duration and dose of gonadotrophins on IVF outcomes. Reprod Biomed Online. 2006;13(5):645\u201350. https:\/\/doi.org\/10.1016\/S1472-6483(10)60654-2.","journal-title":"Reprod Biomed Online"},{"issue":"11\u201312","key":"744_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10815-008-9266-6","volume":"25","author":"DN Lekamge","year":"2008","unstructured":"Lekamge DN, Lane M, Gilchrist RB, Tremellen KP. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J Assist Reprod Genet. 2008;25(11\u201312):515\u201321. https:\/\/doi.org\/10.1007\/s10815-008-9266-6.","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"744_CR25","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.fertnstert.2007.05.055","volume":"89","author":"L Pal","year":"2008","unstructured":"Pal L, Jindal S, Witt BR, Santoro N. Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril. 2008;89(6):1694\u2013701. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.05.055.","journal-title":"Fertil Steril"},{"issue":"9","key":"744_CR26","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/humrep\/dew149","volume":"31","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod. 2016;31(9):1997\u20132004.","journal-title":"Hum Reprod"},{"key":"744_CR27","doi-asserted-by":"crossref","unstructured":"Oudshoorn SC, van Tilborg TC, Eijkemans MJC, Oosterhuis GJE, Friederich J, van Hooff MHA, et al. Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: The predicted hyper responder. Hum Reprod. 2017;32(12):2506\u201314.","DOI":"10.1093\/humrep\/dex319"},{"key":"744_CR28","doi-asserted-by":"crossref","unstructured":"Broekmans FJ. Individualization of FSH Doses in Assisted Reproduction: Facts and Fiction. Front Endocrinol (Lausanne). 2019;10:181.","DOI":"10.3389\/fendo.2019.00181"},{"key":"744_CR29","unstructured":"Mahony MH, B. Richter, K. D'Hooghe, T. Abstracts of the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (P\u2212659); Occurrence and characteristics of recombinant human follicle-stimulating hormone (r-hFSH) dose adjustments during ovarian stimulation in a real-world US database study of 33,962 IVF patient cycles. Hum Reprod. 2018;33(suppl_1):i444."},{"key":"744_CR30","unstructured":"FDA. Highlights of prescribing information for Gonal-f RFF Redi-ject (follitropin alfa injection) 2013 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021684s036lbl.pdf."},{"key":"744_CR31","unstructured":"FDA. Highlights of prescribing information for Follistrim AQ Cartridge (follitropin beta injection) 2004 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021211s011lbl.pdf."},{"issue":"2","key":"744_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rbmo.2011.04.002","volume":"23","author":"WL Ledger","year":"2011","unstructured":"Ledger WL, Fauser BC, Devroey P, Zandvliet AS, Mannaerts BM. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online. 2011;23(2):150\u20139. https:\/\/doi.org\/10.1016\/j.rbmo.2011.04.002.","journal-title":"Reprod Biomed Online"},{"key":"744_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/PPA.S21421","volume":"5","author":"C Abbotts","year":"2011","unstructured":"Abbotts C, Salgado-Braga C, Audibert-Gros C. A redesigned follitropin alfa pen injector for infertility: results of a market research study. Patient Prefer Adherence. 2011;5:315\u201331. https:\/\/doi.org\/10.2147\/PPA.S21421.","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"744_CR34","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1080\/17425247.2017.1237940","volume":"13","author":"F Jeannerot","year":"2016","unstructured":"Jeannerot F, Cusin A, Schertz J. Dose accuracy of the redesigned follitropin alfa pen injector for infertility treatment. Expert Opin Drug Deliv. 2016;13(12):1661\u20139. https:\/\/doi.org\/10.1080\/17425247.2017.1237940.","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"744_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/17425247.2016.1203899","volume":"13","author":"F Jeannerot","year":"2016","unstructured":"Jeannerot F, St\u00fcdeli T, Gunther-LaVergne L, Hirning D, Schertz J. Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment. Expert Opin Drug Deliv. 2016;13(9):1221\u20139. https:\/\/doi.org\/10.1080\/17425247.2016.1203899.","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"744_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/17425247.2019.1651290","volume":"16","author":"S Longobardi","year":"2019","unstructured":"Longobardi S, Seidler A, Martins J, Beckers F, MacGillivray W, D'Hooghe T. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses. Expert Opin Drug Deliv. 2019;16(9):1003\u201314. https:\/\/doi.org\/10.1080\/17425247.2019.1651290.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"744_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/17425247.2017.1289174","volume":"14","author":"J Schertz","year":"2017","unstructured":"Schertz J, Worton H. Patient evaluation of the redesigned follitropin alfa pen injector. Expert Opin Drug Deliv. 2017;14(4):473\u201381. https:\/\/doi.org\/10.1080\/17425247.2017.1289174.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"744_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/17425247.2018.1450386","volume":"15","author":"J Schertz","year":"2018","unstructured":"Schertz J, Worton H. Nurse evaluation of the redesigned fertility pen injector: a questionnaire-based observational survey. Expert Opin Drug Deliv. 2018;15(5):435\u201342. https:\/\/doi.org\/10.1080\/17425247.2018.1450386.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"744_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.rbmo.2014.11.013","volume":"30","author":"F Olivennes","year":"2015","unstructured":"Olivennes F, Trew G, Borini A, Broekmans F, Arriagada P, Warne DW, et al. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reprod Biomed Online. 2015;30(3):248\u201357. https:\/\/doi.org\/10.1016\/j.rbmo.2014.11.013.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"744_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.rbmo.2011.11.014","volume":"24","author":"J Yovich","year":"2012","unstructured":"Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online. 2012;24(3):281\u201392. https:\/\/doi.org\/10.1016\/j.rbmo.2011.11.014.","journal-title":"Reprod Biomed Online"},{"key":"744_CR41","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.2147\/DDDT.S104104","volume":"10","author":"JL Yovich","year":"2016","unstructured":"Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther. 2016;10:2561\u201373. https:\/\/doi.org\/10.2147\/DDDT.S104104.","journal-title":"Drug Des Devel Ther"},{"key":"744_CR42","doi-asserted-by":"crossref","unstructured":"Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370\u20136.","DOI":"10.1093\/humrep\/dev316"},{"key":"744_CR43","doi-asserted-by":"crossref","unstructured":"Malchau SS, Henningsen AA, Forman J, Loft A, Nyboe Andersen A, Pinborg A. Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles. Hum Reprod. 2019;34(1):171\u201380.","DOI":"10.1093\/humrep\/dey341"},{"key":"744_CR44","doi-asserted-by":"crossref","unstructured":"Polyzos NP, Sunkara SK. Sub-optimal responders following controlled ovarian stimulation: an overlooked group? Hum Reprod. 2015;30(9):2005\u20138.","DOI":"10.1093\/humrep\/dev149"},{"issue":"6","key":"744_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559\u201377. https:\/\/doi.org\/10.1093\/humupd\/8.6.559.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"744_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.fertnstert.2009.02.049","volume":"94","author":"PS Gera","year":"2010","unstructured":"Gera PS, Tatpati LL, Allemand MC, Wentworth MA, Coddington CC. Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome. Fertil Steril. 2010;94(1):173\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.02.049.","journal-title":"Fertil Steril"},{"issue":"2","key":"744_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91\u2013108. https:\/\/doi.org\/10.1111\/j.1471-1842.2009.00848.x.","journal-title":"Health Info Libr J"},{"issue":"4","key":"744_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.rbmo.2017.01.012","volume":"34","author":"A Allegra","year":"2017","unstructured":"Allegra A, Marino A, Volpes A, Coffaro F, Scaglione P, Gullo S, et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF\/ICSI cycles. Reprod Biomed Online. 2017;34(4):429\u201338. https:\/\/doi.org\/10.1016\/j.rbmo.2017.01.012.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"744_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-7827-12-6","volume":"12","author":"K Buhler","year":"2014","unstructured":"Buhler K, Naether OG, Bilger W. A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology. Reprod Biol Endocrinol. 2014;12(1):6. https:\/\/doi.org\/10.1186\/1477-7827-12-6.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"744_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","volume":"97","author":"P Devroey","year":"2012","unstructured":"Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. Menopur in Gn RHACwSETTG. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561\u201371. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.016.","journal-title":"Fertil Steril"},{"key":"744_CR51","doi-asserted-by":"crossref","unstructured":"Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, et al. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod. 2008;23(2):421\u20136.","DOI":"10.1093\/humrep\/dem388"},{"issue":"4","key":"744_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.rbmo.2017.06.019","volume":"35","author":"JJ Espin\u00f3s","year":"2017","unstructured":"Espin\u00f3s JJ, Polo A, Sanchez-Hernandez J, Bordas R, Pares P, Martinez O, et al. Weight decrease improves live birth rates in obese women undergoing IVF: a pilot study. Reprod Biomed Online. 2017;35(4):417\u201324. https:\/\/doi.org\/10.1016\/j.rbmo.2017.06.019.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"744_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1477-7827-7-111","volume":"7","author":"SC Esteves","year":"2009","unstructured":"Esteves SC, Schertz JC, Verza S Jr, Schneider DT, Zabaglia SF. A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection. Reprod Biol Endocrinol. 2009;7(1):111. https:\/\/doi.org\/10.1186\/1477-7827-7-111.","journal-title":"Reprod Biol Endocrinol"},{"key":"744_CR54","doi-asserted-by":"crossref","unstructured":"Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063\u201372.","DOI":"10.1093\/humrep\/dep291"},{"issue":"5","key":"744_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1472-6483(10)60310-0","volume":"17","author":"NL Freiesleben","year":"2008","unstructured":"Freiesleben NL, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Loft A, et al. Predictors of ovarian response in intrauterine insemination patients and development of a dosage nomogram. Reprod Biomed Online. 2008;17(5):632\u201341. https:\/\/doi.org\/10.1016\/S1472-6483(10)60310-0.","journal-title":"Reprod Biomed Online"},{"key":"744_CR56","doi-asserted-by":"crossref","unstructured":"Kyrou D, Popovic-Todorovic B, Fatemi HM, Bourgain C, Haentjens P, Van Landuyt L, et al. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH\/GnRH antagonist? Hum Reprod. 2009;24(11):2902\u20139.","DOI":"10.1093\/humrep\/dep290"},{"key":"744_CR57","doi-asserted-by":"crossref","unstructured":"Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsboll S, Andersen AN. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod. 2008;23(8):1820\u20139.","DOI":"10.1093\/humrep\/den131"},{"key":"744_CR58","doi-asserted-by":"crossref","unstructured":"Magnusson A, Nilsson L, Olerod G, Thurin-Kjellberg A, Bergh C. The addition of anti-Mullerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial. Hum Reprod. 2017;32(4):811\u20139.","DOI":"10.1093\/humrep\/dex012"},{"issue":"1","key":"744_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.rbmo.2009.10.009","volume":"20","author":"GS Nakhuda","year":"2010","unstructured":"Nakhuda GS, Douglas NC, Thornton MH, Guarnaccia MM, Lobo R, Sauer MV. Anti-Mullerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reprod Biomed Online. 2010;20(1):42\u20137. https:\/\/doi.org\/10.1016\/j.rbmo.2009.10.009.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"744_CR60","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/humrep\/dem317","volume":"23","author":"A Nyboe Andersen","year":"2008","unstructured":"Nyboe Andersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsboll S, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod. 2008;23(2):427\u201334.","journal-title":"Hum Reprod"},{"issue":"1","key":"744_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/14647270903586356","volume":"13","author":"A Requena","year":"2010","unstructured":"Requena A, Landeras JL, Martinez-Navarro L, Calatayud C, Sanchez F, Maldonado V, et al. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles? Hum Fertil (Camb). 2010;13(1):41\u20139. https:\/\/doi.org\/10.3109\/14647270903586356.","journal-title":"Hum Fertil (Camb)"},{"issue":"5","key":"744_CR62","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.rbmo.2015.01.005","volume":"30","author":"M Rettenbacher","year":"2015","unstructured":"Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, et al. A multi-Centre phase 3 study comparing efficacy and safety of Bemfola((R)) versus Gonal-f((R)) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015;30(5):504\u201313. https:\/\/doi.org\/10.1016\/j.rbmo.2015.01.005.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"744_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-015-0135-8","volume":"14","author":"T Strowitzki","year":"2016","unstructured":"Strowitzki T, Kuczynski W, Mueller A, Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap(R) (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol. 2016;14(1):1. https:\/\/doi.org\/10.1186\/s12958-015-0135-8.","journal-title":"Reprod Biol Endocrinol"},{"key":"744_CR64","unstructured":"Longobardi S.; D\u2019Hooghe T. Comments on the results of the ESTHER-1 trial (Evidence-based Stimulation Trial with human rFSH in Europe and Rest of world 1). Available at: https:\/\/www.fertstertdialog.com\/users\/16110-fertility-and-sterility\/posts\/12852-23086. 2017."},{"key":"744_CR65","unstructured":"Wilkinson J. Comments on the results of the ESTHER-1 trial (Evidence-based Stimulation Trial with human rFSH in Europe and Rest of world 1). Available at: https:\/\/www.fertstertdialog.com\/users\/16110-fertility-and-sterility\/posts\/12852-23086. 2017."},{"issue":"5","key":"744_CR66","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0015-0282(00)00471-4","volume":"73","author":"I Cedrin-Durnerin","year":"2000","unstructured":"Cedrin-Durnerin I, Bstandig B, Herve F, Wolf J, Uzan M, Hugues J. A comparative study of high fixed-dose and decremental-dose regimens of gonadotropins in a minidose gonadotropin-releasing hormone agonist flare protocol for poor responders. Fertil Steril. 2000;73(5):1055\u20136. https:\/\/doi.org\/10.1016\/S0015-0282(00)00471-4.","journal-title":"Fertil Steril"},{"issue":"3","key":"744_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/oxfordjournals.humrep.a138053","volume":"8","author":"MH van Hooff","year":"1993","unstructured":"van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod. 1993;8(3):369\u201373.","journal-title":"Hum Reprod"},{"key":"744_CR68","unstructured":"Yovich JL, Hinchliffe PM, Lingam S, Srinivasan S, Keane KN. Adjusting the PIVET rFSH dosing algorithm for the biosimilar Bemfola product. J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol. 2018;5:3."},{"issue":"11","key":"744_CR69","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1093\/humrep\/dem270","volume":"22","author":"JA Huirne","year":"2007","unstructured":"Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22(11):2805\u201313.","journal-title":"Hum Reprod"},{"issue":"3","key":"744_CR70","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/humrep\/deh668","volume":"20","author":"LP Cheung","year":"2005","unstructured":"Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20(3):616\u201321.","journal-title":"Hum Reprod"},{"issue":"2","key":"744_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0950-3552(05)80085-9","volume":"6","author":"K Gordon","year":"1992","unstructured":"Gordon K, Hodgen GD. GnRH agonists and antagonists in assisted reproduction. Baillieres Clin Obstet Gynaecol. 1992;6(2):247\u201365. https:\/\/doi.org\/10.1016\/S0950-3552(05)80085-9.","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"744_CR72","volume":"5","author":"HG Al-Inany","year":"2011","unstructured":"Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"744_CR73","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560\u201379. https:\/\/doi.org\/10.1093\/humupd\/dmx017.","journal-title":"Hum Reprod Update"},{"issue":"9","key":"744_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106854","volume":"9","author":"JS Xiao","year":"2014","unstructured":"Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014;9(9):e106854. https:\/\/doi.org\/10.1371\/journal.pone.0106854.","journal-title":"PLoS One"},{"issue":"1","key":"744_CR75","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rbmo.2011.09.017","volume":"24","author":"J Pundir","year":"2012","unstructured":"Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online. 2012;24(1):6\u201322. https:\/\/doi.org\/10.1016\/j.rbmo.2011.09.017.","journal-title":"Reprod Biomed Online"},{"key":"744_CR76","first-page":"Cd001750","volume":"4","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:Cd001750.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"744_CR77","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/humrep\/der251","volume":"26","author":"P Devroey","year":"2011","unstructured":"Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593\u20137.","journal-title":"Hum Reprod"},{"key":"744_CR78","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fendo.2019.00281","volume":"10","author":"V Grisendi","year":"2019","unstructured":"Grisendi V, Mastellari E, La Marca A. Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. Front Endocrinol (Lausanne). 2019;10:281.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"744_CR79","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jcem.85.9.6767","volume":"85","author":"AL Schneyer","year":"2000","unstructured":"Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, et al. Dynamic changes in the intrafollicular inhibin\/activin\/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab. 2000;85(9):3319\u201330. https:\/\/doi.org\/10.1210\/jcem.85.9.6767.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"744_CR80","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.fertnstert.2018.02.128","volume":"109","author":"B Lawrenz","year":"2018","unstructured":"Lawrenz B, Labarta E, Fatemi H, Bosch E. Premature progesterone elevation: targets and rescue strategies. Fertil Steril. 2018;109(4):577\u201382. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.02.128.","journal-title":"Fertil Steril"},{"key":"744_CR81","volume":"8","author":"I Kwan","year":"2014","unstructured":"Kwan I, Bhattacharya S, Kang A, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev. 2014;8:CD005289.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"744_CR82","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, Practice Committee of the American Society for Reproductive M","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, Practice Committee of the American Society for Reproductive M. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634\u201347. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.08.048.","journal-title":"Fertil Steril"},{"key":"744_CR83","doi-asserted-by":"crossref","unstructured":"Golan A, Herman A, Soffer Y, Bukovsky I, Ron-El R. Ultrasonic control without hormone determination for ovulation induction in in-vitro fertilization\/embryo transfer with gonadotrophin-releasing hormone analogue and human menopausal gonadotrophin. Hum Reprod. 1994;9(9):1631\u20133.","DOI":"10.1093\/oxfordjournals.humrep.a138764"},{"issue":"6","key":"744_CR84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/09513590.2011.633666","volume":"28","author":"A Wiser","year":"2012","unstructured":"Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Monitoring stimulated cycles during in vitro fertilization treatment with ultrasound only--preliminary results. Gynecol Endocrinol. 2012;28(6):429\u201331. https:\/\/doi.org\/10.3109\/09513590.2011.633666.","journal-title":"Gynecol Endocrinol"},{"key":"744_CR85","doi-asserted-by":"crossref","unstructured":"Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod, 2005. 20(3):611\u20135.","DOI":"10.1093\/humrep\/deh663"},{"issue":"5","key":"744_CR86","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S1472-6483(10)61098-X","volume":"8","author":"MA Aboulghar","year":"2004","unstructured":"Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online. 2004;8(5):524\u20137. https:\/\/doi.org\/10.1016\/S1472-6483(10)61098-X.","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"744_CR87","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1023\/A:1009470602525","volume":"17","author":"MA Aboulghar","year":"2000","unstructured":"Aboulghar MA, Mansour RT, Serour GI, Rhodes CA, Amin YM. Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation. J Assist Reprod Genet. 2000;17(5):298\u2013301. https:\/\/doi.org\/10.1023\/A:1009470602525.","journal-title":"J Assist Reprod Genet"},{"issue":"5","key":"744_CR88","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/humrep\/dey061","volume":"33","author":"A La Marca","year":"2018","unstructured":"La Marca A, Blockeel C, Bosch E, Fanchin R, Fatemi HM, Fauser BC, et al. Individualized FSH dosing improves safety and reduces iatrogenic poor response while maintaining live-birth rates. Hum Reprod. 2018;33(5):982\u20133.","journal-title":"Hum Reprod"},{"issue":"5","key":"744_CR89","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/humrep\/dey062","volume":"33","author":"SK Sunkara","year":"2018","unstructured":"Sunkara SK, Polyzos NP. OPTIMIST trial: optimistic evidence? Hum Reprod. 2018;33(5):983\u20134.","journal-title":"Hum Reprod"},{"issue":"3","key":"744_CR90","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/humupd\/8.3.291","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update. 2002;8(3):291\u20136. https:\/\/doi.org\/10.1093\/humupd\/8.3.291.","journal-title":"Hum Reprod Update"},{"key":"744_CR91","doi-asserted-by":"crossref","unstructured":"D'Angelo A, Amso NN, Hassan R. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2017;5(5):Cd002811.","DOI":"10.1002\/14651858.CD002811.pub4"},{"key":"744_CR92","first-page":"i121","volume":"19","author":"VP Kamthane","year":"2004","unstructured":"Kamthane VP, Goswami SK, Ghosh S, Chattopadhyay R, Chakravarty BN. Does coasting prevent OHSS without compromising pregnancy outcome? Hum Reprod. 2004;19:i121.","journal-title":"Hum Reprod"},{"issue":"11","key":"744_CR93","first-page":"812","volume":"82","author":"L Lukaszuk","year":"2011","unstructured":"Lukaszuk L, Liss J, Jakiel G. Internal Coasting' for prevention of ovarian hyperstimulation syndrome (OHSS) in IVF\/ICSI. Ginekol Pol. 2011;82(11):812\u20136.","journal-title":"Ginekol Pol"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-021-00744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-021-00744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T05:06:52Z","timestamp":1620709612000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-021-00744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/s12958-021-00744-x","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HR received speaker fees\/honoraria\/grants from MSD, Ferring, Besin, Merck KGaA (Darmstadt, Germany) and Sun Pharma; WB is an employee of Merck Serono GmbH, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; DD is an employee of EMD Serono Research & Development Institute, Rockland, MA, USA, a business of Merck KGaA, Darmstadt, Germany; GG reports honoraria and\/or non-financial support from ObsEva, Merck KGaA (Darmstadt, Germany), MSD, Ferring, Abbott, Gedeon-Richter, Theramex, Guerbet, Finox, Glycotope and ReprodWissen GmbH; ALM received research grants and speaker fees from Merck KGaA (Darmstadt, Germany), Ferring, MSD, IBSA, Gedeon Richter, TEVA, Beckman Coulter<b>;<\/b> SL and TDH are employees of Merck KGaA, Darmstadt, Germany; MM is an employee of EMD Serono Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany; XY is an employee of EMD Serono Research & Development Institute, Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}